Nuvation Bio Inc. $NUVB Stock Holdings Boosted by Cwm LLC

Cwm LLC increased its position in Nuvation Bio Inc. (NYSE:NUVB) by 169.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 102,328 shares of the company’s stock after acquiring an additional 64,365 shares during the period. Cwm LLC’s holdings in Nuvation Bio were worth $379,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Highline Wealth Partners LLC bought a new position in Nuvation Bio in the 2nd quarter worth about $25,000. Rangeley Capital LLC bought a new position in Nuvation Bio in the 2nd quarter worth approximately $25,000. Cetera Investment Advisers bought a new position in Nuvation Bio in the 2nd quarter worth approximately $29,000. Captrust Financial Advisors bought a new stake in Nuvation Bio during the 2nd quarter valued at $32,000. Finally, Kingswood Wealth Advisors LLC bought a new stake in Nuvation Bio during the 2nd quarter valued at $42,000. 61.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently commented on NUVB. B. Riley started coverage on Nuvation Bio in a report on Wednesday, November 19th. They set a “buy” rating and a $12.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvation Bio in a research note on Wednesday, October 8th. Truist Financial set a $11.00 price target on shares of Nuvation Bio in a research report on Monday, November 24th. Citizens Jmp increased their price objective on shares of Nuvation Bio from $8.00 to $10.00 and gave the company a “market outperform” rating in a report on Thursday, November 20th. Finally, Royal Bank Of Canada raised their price objective on shares of Nuvation Bio from $7.00 to $8.00 and gave the company an “outperform” rating in a research note on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Nuvation Bio currently has a consensus rating of “Moderate Buy” and an average price target of $10.50.

Nuvation Bio Stock Performance

Shares of NUVB opened at $8.03 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.48 and a quick ratio of 8.39. The firm’s 50 day moving average is $7.58 and its 200-day moving average is $4.62. Nuvation Bio Inc. has a 12-month low of $1.54 and a 12-month high of $9.75. The stock has a market capitalization of $2.75 billion, a P/E ratio of -12.55 and a beta of 1.54.

Nuvation Bio (NYSE:NUVB) last issued its earnings results on Monday, November 3rd. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01. The firm had revenue of $13.12 million during the quarter, compared to analysts’ expectations of $7.48 million. Nuvation Bio had a negative net margin of 813.07% and a negative return on equity of 54.99%. Equities research analysts anticipate that Nuvation Bio Inc. will post -0.36 EPS for the current fiscal year.

Insider Buying and Selling at Nuvation Bio

In related news, insider Gary Hattersley sold 100,000 shares of Nuvation Bio stock in a transaction on Monday, October 27th. The stock was sold at an average price of $5.02, for a total value of $502,000.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Dongfang Liu sold 150,000 shares of the company’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $7.82, for a total value of $1,173,000.00. Following the sale, the insider directly owned 18,000 shares of the company’s stock, valued at approximately $140,760. This represents a 89.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 320,000 shares of company stock valued at $2,050,800. Corporate insiders own 29.93% of the company’s stock.

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.